tolvaptan has been researched along with Acquired Nephrogenic Diabetes Insipidus in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Capasso, G; Cordat, E; Costanzo, V; Guarino, S; Iervolino, A; Jelen, S; La Manna, A; Marzuillo, P; Miraglia Del Giudice, E; Perna, AF; Prosperi, F; Suzumoto, Y; Trepiccione, F; Zacchia, M | 1 |
| Ando, F; Kagechika, H; Kondo, Y; Mori, S; Morimoto, T; Nomura, N; Rai, T; Sasaki, S; Sohara, E; Uchida, S; Yui, N | 1 |
| Giuliani, C; Peri, A | 1 |
| Akioka, Y; Fujita, T; Hashimoto, M; Hisano, M; Igarashi, T; Iida, A; Iiri, T; Makita, N; Manaka, K; Miura, K; Sekine, T; Takahashi, K; Takubo, N; Ueda, N | 1 |
| Hatano, M; Imamura, T; Inaba, T; Kato, N; Kinugawa, K; Kyo, S; Maki, H; Minatsuki, S; Muraoka, H; Nagai, R; Shiga, T; Yao, A | 1 |
| Dohi, K; Ito, M; Watanabe, K | 1 |
| Greenberg, A; Verbalis, JG | 1 |
2 review(s) available for tolvaptan and Acquired Nephrogenic Diabetes Insipidus
| Article | Year |
|---|---|
Management of euvolemic hyponatremia attributed to SIADH in the hospital setting.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Volume; Body Water; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Demeclocycline; Diabetes Insipidus, Nephrogenic; Disease Management; Drug Interactions; Hospitalization; Humans; Hydrocortisone; Hyponatremia; Hypothyroidism; Inappropriate ADH Syndrome; Kidney Tubules, Collecting; Lithium; Multicenter Studies as Topic; Osmolar Concentration; Paraneoplastic Syndromes; Saline Solution, Hypertonic; Tolvaptan | 2014 |
Vasopressin receptor antagonists.
Topics: Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Clinical Trials as Topic; Diabetes Insipidus, Nephrogenic; Fibrosis; Heart Failure; Humans; Hyponatremia; Osmolar Concentration; Polycystic Kidney Diseases; Pyrroles; Receptors, Vasopressin; Sodium; Tolvaptan; United States; United States Food and Drug Administration; Vasopressins | 2006 |
1 trial(s) available for tolvaptan and Acquired Nephrogenic Diabetes Insipidus
| Article | Year |
|---|---|
Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Urea Nitrogen; Creatine; Diabetes Insipidus, Nephrogenic; Diuretics; Drug Monitoring; Female; Heart Failure; Humans; Hypovolemia; Logistic Models; Male; Middle Aged; Osmolar Concentration; Potassium; Predictive Value of Tests; Renal Insufficiency, Chronic; Sensitivity and Specificity; Sodium; Tolvaptan; Ultrasonography; Urine; Young Adult | 2013 |
4 other study(ies) available for tolvaptan and Acquired Nephrogenic Diabetes Insipidus
| Article | Year |
|---|---|
Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Cell Line; Cell Membrane; Chlorocebus aethiops; COS Cells; Diabetes Insipidus, Nephrogenic; Dogs; Endoplasmic Reticulum; Humans; Madin Darby Canine Kidney Cells; Male; Mutation; Protein Transport; Receptors, Vasopressin; Tolvaptan; Vasopressins | 2020 |
AKAPs-PKA disruptors increase AQP2 activity independently of vasopressin in a model of nephrogenic diabetes insipidus.
Topics: A Kinase Anchor Proteins; Amino Acid Sequence; Animals; Aquaporin 2; Arginine Vasopressin; Benzazepines; Benzhydryl Compounds; Cell Line, Transformed; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Insipidus, Nephrogenic; Disease Models, Animal; Epithelial Cells; Gene Expression Regulation; Humans; Kidney Tubules, Collecting; Male; Mice, Inbred C57BL; Osmolar Concentration; Phenols; Protein Binding; Receptors, Vasopressin; Tolvaptan; Water | 2018 |
V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.
Topics: Amino Acid Substitution; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cell Membrane; Child; Child, Preschool; Chlorocebus aethiops; COS Cells; Diabetes Insipidus, Nephrogenic; Humans; Male; Mutation, Missense; Neurophysins; Protein Precursors; Receptors, Vasopressin; Tolvaptan; Vasopressins | 2012 |
Urine osmolality-guided tolvaptan therapy in decompensated heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diabetes Insipidus, Nephrogenic; Drug Monitoring; Female; Heart Failure; Humans; Male; Tolvaptan | 2013 |